These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10837448)

  • 1. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Christenson JC; Korgenski EK; Daly JA
    J Antimicrob Chemother; 2000 Jun; 45(6):899-901. PubMed ID: 10837448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.
    Bonfiglio G; Marchetti F
    Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    Diagn Microbiol Infect Dis; 1997 Oct; 29(2):81-6. PubMed ID: 9368083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of pseudomonas aeruginosa to cefepime versus ceftazidime in patients with cystic fibrosis.
    Robinson CA; Kuhn RJ; Craigmyle J; Anstead MI; Kanga JE
    Pharmacotherapy; 2001 Nov; 21(11):1320-4. PubMed ID: 11714203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains.
    Bantar C; Di Chiara M; Nicola F; Relloso S; Smayevsky J
    Diagn Microbiol Infect Dis; 2000 May; 37(1):41-4. PubMed ID: 10794939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa.
    Hikida M; Yamazaki Y; Yoshida M; Kawashima K; Nishiki K; Mitsuhashi S
    J Antibiot (Tokyo); 1995 Aug; 48(8):891-2. PubMed ID: 7592037
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
    Buehrle DJ; Shields RK; Chen L; Hao B; Press EG; Alkrouk A; Potoski BA; Kreiswirth BN; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2016 May; 60(5):3227-31. PubMed ID: 26976862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of meropenem and four other antibiotics against 554 clinical strains obtained from Beijing in 1999.
    Wang H; Chen M; Xie X; Xu Y; Zhang X; Zhang Y; Yuan Y; Wang C; Liu J; Wang P
    J Infect Chemother; 2000 Sep; 6(3):178-83. PubMed ID: 11810561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Pahlavanzadeh F; Kalantar-Neyestanaki D; Motamedifar M; Mansouri S
    Yale J Biol Med; 2020 Mar; 93(1):29-34. PubMed ID: 32226332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
    Cabot G; Ocampo-Sosa AA; Tubau F; Macia MD; Rodríguez C; Moya B; Zamorano L; Suárez C; Peña C; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2011 May; 55(5):1906-11. PubMed ID: 21357294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM; Brown SD
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on antibiotics susceptibility and mechanism of carbapenem-resistance in clinical isolates of Pseudomonas aeruginosa].
    Arita K; Daido K; Ohashi N; Nakamura K; Takeshima Y; Kohara T
    Jpn J Antibiot; 1999 Jul; 52(7):491-6. PubMed ID: 10516928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.